ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
70,800
-200 (-0.28%)
Jun 20, 2025, 3:30 PM KST
221.82%
Market Cap 3.44T
Revenue (ttm) 27.63B
Net Income (ttm) -71.71B
Shares Out 48.53M
EPS (ttm) -1,489.50
PE Ratio n/a
Forward PE 83.36
Dividend n/a
Ex-Dividend Date n/a
Volume 848,364
Average Volume 1,047,160
Open 72,700
Previous Close 71,000
Day's Range 69,800 - 72,700
52-Week Range 21,400 - 84,000
Beta 0.82
RSI 48.49
Earnings Date Aug 11, 2025

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

In 2024, ABL Bio's revenue was 33.40 billion, a decrease of -49.04% compared to the previous year's 65.55 billion. Losses were -55.53 billion, 1998.1% more than in 2023.

Financial Statements

News

There is no news available yet.